Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1596

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    PL02 - Innovation to Bridge Lung Cancer Care Tomorrow (Japanese, Mandarin, Spanish Translation Available)

    • Type: Plenary
    • Track: N.A.
    • +

      PL02.01 - Chair

      07:00 - 07:00  |  Presenting Author(s): Clarissa Mathias

      • Abstract

      Abstract not provided

    • +

      PL02.02 - Chair

      07:00 - 07:00  |  Presenting Author(s): James Chih-Hsin Yang

      • Abstract

      Abstract not provided

    • +

      PL02.03 - Human Data Science and the Omics Revolution: What Does It Mean for Oncology Patients?

      07:00 - 07:20  |  Presenting Author(s): Patrick Tan

      • Abstract

      Abstract not provided

    • +

      PL02.05 - Challenges in Clinical Application of Precision Medicine: From Targeted Therapies to Immunotherapy: Advanced Non-Small Cell Lung Cancer (NSCLC) as a Model

      07:20 - 07:40  |  Presenting Author(s): David R. Gandara

      • Abstract

      Loading...

    • +

      PL02.06 - Patient-Directed Innovation, Research and Clinical Trials

      07:40 - 08:00  |  Presenting Author(s): Lisa C Goldman

      • Abstract

      Loading...

    • +

      PL02.07 - Translational Medicine: An Engine of Change for Bringing New Technology to the Community

      08:00 - 08:20  |  Presenting Author(s): Michael Boyer

      • Abstract

      Loading...

    • +

      PL02.08 - Live Q&A

      08:20 - 09:00

      • Abstract

      Abstract not provided

  • +

    ES01 - Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC

    • Type: Educational Session
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      ES01.01 - Non-Squamous

      09:15 - 09:35  |  Presenting Author(s): Virote Sriuranpong

      • Abstract

      Abstract not provided

    • +

      ES01.02 - Choosing Systemic Therapies After Chemoimmunotherapy – Squamous

      09:35 - 09:55  |  Presenting Author(s): Claudio Marcelo Martin

      • Abstract

      Loading...

    • +

      ES01.03 - Systemic Therapy after Chemo IO in Small Cell Lung Cancer

      09:55 - 10:15  |  Presenting Author(s): Charu Aggarwal

      • Abstract

      Abstract not provided

  • +

    OA01 - Established Drugs in Special Populations and New Drugs in Established Populations

    • Type: Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      OA01.01 - Chair

      09:15 - 09:15  |  Presenting Author(s): Noemi Reguart

      • Abstract

      Abstract not provided

    • +

      OA01.02 - Chair

      09:15 - 09:15  |  Presenting Author(s): Jiuwei Cui

      • Abstract

      Abstract not provided

    • +

      OA01.03 - Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

      09:15 - 09:25  |  Presenting Author(s): Saadettin Kilickap

      • Abstract

      Loading...

    • +

      OA01.04 - Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A

      09:25 - 09:35  |  Presenting Author(s): Fred R Hirsch

      • Abstract

      Loading...

    • +

      OA01.05 - Discussant

      09:35 - 09:40  |  Presenting Author(s): Edward B. Garon

      • Abstract

      Abstract not provided

    • +

      OA01.06 - Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC

      09:40 - 09:50  |  Presenting Author(s): Gillianne Geet Yi Lai

      • Abstract

      Loading...

    • +

      OA01.07 - A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC

      09:50 - 10:00  |  Presenting Author(s): Matthew G. Krebs

      • Abstract

      Loading...

    • +

      OA01.08 - Discussant

      10:00 - 10:05  |  Presenting Author(s): Justin Gainor

      • Abstract

      Abstract not provided

    • +

      OA01.09 - Live Q&A

      10:05 - 10:15

      • Abstract

      Abstract not provided

  • +

    OA02 - Updates in Locally Advanced NSCLC

    • Type: Oral
    • Track: Locoregional and Oligometastatic Disease
    • +

      OA02.01 - Chair

      09:15 - 09:15  |  Presenting Author(s): Kenichi Suda

      • Abstract

      Abstract not provided

    • +

      OA02.02 - Chair

      09:15 - 09:15  |  Presenting Author(s): Antoinette Wozniak

      • Abstract

      Abstract not provided

    • +

      OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799

      09:15 - 09:25  |  Presenting Author(s): Martin Reck

      • Abstract

      Loading...

    • +

      OA02.04 - Randomized Phase Ⅱ Trial (RTOG1106) on Midtreatment PET/CT Guided Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer

      09:25 - 09:35  |  Presenting Author(s): Feng-Ming (Spring) Kong

      • Abstract

      Loading...

    • +

      OA02.05 - Local, Regional and Pulmonary Failures in the Randomised PET-Boost Trial for NSCLC Patients

      09:35 - 09:45  |  Presenting Author(s): Saskia Anne Cooke

      • Abstract

      Loading...

    • +

      OA02.06 - PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC

      09:45 - 09:55  |  Presenting Author(s): Nan Bi

      • Abstract

      Loading...

    • +

      OA02.07 - Discussant

      09:55 - 10:05  |  Presenting Author(s): You Lu

      • Abstract

      Abstract not provided

    • +

      OA02.08 - Live Q&A

      10:05 - 10:15

      • Abstract

      Abstract not provided

  • +

    ES02 - Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?

    • Type: Educational Session
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      ES02.01 - We Should Choose Treatment Based on PD-L1, TMB and Other Biomarkers

      10:30 - 10:45  |  Presenting Author(s): Ticiana A Leal

      • Abstract

      Abstract not provided

    • +

      ES02.02 - Immune Checkpoint Blockade for All NSCLC Regardless of PD-L1, TMB or Other Biomarkers

      10:45 - 11:00  |  Presenting Author(s): Naiyer Rizvi

      • Abstract

      Abstract not provided

    • +

      ES02.03 - We Should Use IO Alone as Maintenance

      11:00 - 11:15  |  Presenting Author(s): Roy S. Herbst

      • Abstract

      Abstract not provided

    • +

      ES02.04 - We Should Use Combination of IO and Chemotherapy as Maintenance

      11:15 - 11:30  |  Presenting Author(s): Marina Chiara Garassino

      • Abstract

      Abstract not provided

  • +

    ES03 - Understanding and Treating Oligometastatic Diseases

    • Type: Educational Session
    • Track: Locoregional and Oligometastatic Disease
    • +

      ES03.01 - Chair

      10:30 - 10:30  |  Presenting Author(s): Linda W Martin

      • Abstract

      Abstract not provided

    • +

      ES03.02 - Chair

      10:30 - 10:30  |  Presenting Author(s): Yasushi Nagata

      • Abstract

      Abstract not provided

    • +

      ES03.03 - Characterization and Classification of Oligometastatic Disease

      10:30 - 10:42  |  Presenting Author(s): Matthias Guckenberger

      • Abstract

      Abstract not provided

    • +

      ES03.04 - Timing of Systemic Therapy in OMD

      10:42 - 10:54  |  Presenting Author(s): Simon Ekman

      • Abstract

      Loading...

    • +

      ES03.05 - Surgery as a Component of Local Consolidative Therapy

      10:54 - 11:06  |  Presenting Author(s): Mara B Antonoff

      • Abstract

      Loading...

    • +

      ES03.06 - Radiation as a Component of Treatment for Oligometastatic Disease

      11:06 - 11:18  |  Presenting Author(s): Kevin Lee Min Chua

      • Abstract

      Abstract not provided

    • +

      ES03.07 - Live Q&A

      11:18 - 11:30

      • Abstract

      Abstract not provided

  • +

    OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC

    • Type: Oral
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      OA03.01 - Chair

      10:30 - 10:30  |  Presenting Author(s): Jhanelle Elaine Gray

      • Abstract

      Abstract not provided

    • +

      OA03.02 - Chair

      10:30 - 10:30  |  Presenting Author(s): Sukhmani K. Padda

      • Abstract

      Abstract not provided

    • +

      OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

      10:30 - 10:40  |  Presenting Author(s): Alex I. Spira

      • Abstract

      Loading...

    • +

      OA03.04 - Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC

      10:40 - 10:50  |  Presenting Author(s): Helena Yu

      • Abstract

      Loading...

    • +

      OA03.05 - Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

      10:50 - 11:00  |  Presenting Author(s): Atsushi Nakamura

      • Abstract

      Loading...

    • +

      OA03.06 - Discussant

      11:00 - 11:10  |  Presenting Author(s): Ignatius Ou

      • Abstract

      Abstract not provided

    • +

      OA03.07 - Live Q&A

      11:10 - 11:30

      • Abstract

      Abstract not provided

  • +

    ES04 - Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond

    • Type: Educational Session
    • Track: Locoregional and Oligometastatic Disease
    • +

      ES04.01 - Navigating the Evaluation of Novel Systemic Agents in Stage III Disease

      11:45 - 12:05  |  Presenting Author(s): Karen Kelly

      • Abstract

      Loading...

    • +

      ES04.02 - Biology Guided Adaptive Radiation Therapy (BigART) and Personalized Immunotherapy in Unresectable Stage

      12:05 - 12:25  |  Presenting Author(s): Feng-Ming (Spring) Kong

      • Abstract

      Abstract not provided

    • +

      ES04.03 - Extending Durvalumab Maintenance to Special Populations

      12:25 - 12:45  |  Presenting Author(s): Raffaele Califano

      • Abstract

      Abstract not provided

  • +

    MA01 - Novel Systemic Treatment in NSCLC

    • Type: Mini Oral
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      MA01.01 - Chair

      11:45 - 11:45  |  Presenting Author(s): Thanyanan Reungwetwattana

      • Abstract

      Abstract not provided

    • +

      MA01.02 - Chair

      11:45 - 11:45  |  Presenting Author(s): Julia K Rotow

      • Abstract

      Abstract not provided

    • +

      MA01.03 - The Role of Gut Microbiome in the Efficacy of Chemotherapy in Patients With Locally Advanced and Advanced Lung Cancer

      11:45 - 11:50  |  Presenting Author(s): Zhe Zhao

      • Abstract

      Loading...

    • +

      MA01.04 - A Randomized Study Comparing Cisplatin/Paclitaxel Liposome vs Cisplatin/Gemcitabine in Chemonaive, Advanced Squamous NSCLC

      11:50 - 11:55  |  Presenting Author(s): Caicun Zhou

      • Abstract

      Loading...

    • +

      MA01.05 - Clinical Efficacy and Safety of Pemetrexed With or Without Either Bevacizumab or Pembrolizumab in Patients With Metastatic NSCLC

      11:55 - 12:00  |  Presenting Author(s): Wang Chun Kwok

      • Abstract

      Loading...

    • +

      MA01.06 - Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC

      12:00 - 12:05  |  Presenting Author(s): Joaquim Bosch-Barrera

      • Abstract

      Loading...

    • +

      MA01.07 - Discussant

      12:05 - 12:10  |  Presenting Author(s): Benjamin Levy

      • Abstract

      Abstract not provided

    • +

      MA01.08 - Gemcitabine Plus Capecitabine in Patients With Primary Pulmonary Lymphoepithelioma-Like Carcinoma Previously Treated With Chemotherapy

      12:10 - 12:15  |  Presenting Author(s): Ying Liang

      • Abstract

      Loading...

    • +

      MA01.09 - Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)

      12:15 - 12:20  |  Presenting Author(s): Saad A. Khan

      • Abstract

      Loading...

    • +

      MA01.10 - MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations

      12:20 - 12:25  |  Presenting Author(s): Hao Sun

      • Abstract

      Loading...

    • +

      MA01.11 - CD47 Agonist Peptide PKHB1 Induced Cell Death in NSCLC via Triggering Endoplasmic Reticulum Stress

      12:25 - 12:30  |  Presenting Author(s): Jiani Ye

      • Abstract

      Loading...

    • +

      MA01.12 - Discussant

      12:30 - 12:35  |  Presenting Author(s): Will Lockwood

      • Abstract

      Abstract not provided

    • +

      MA01.13 - Live Q&A

      12:35 - 12:45

      • Abstract

      Abstract not provided

  • +

    OA04 - New Data from Rare EGFR Alterations

    • Type: Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      OA04.01 - Chair

      11:45 - 11:45  |  Presenting Author(s): Hossein Borghaei

      • Abstract

      Abstract not provided

    • +

      OA04.02 - Chair

      11:45 - 11:45  |  Presenting Author(s): Jason Porter

      • Abstract

      Abstract not provided

    • +

      OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

      11:45 - 11:55  |  Presenting Author(s): Caicun Zhou

      • Abstract

      Loading...

    • +

      OA04.04 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

      11:55 - 12:05  |  Presenting Author(s): Joshua K. Sabari

      • Abstract

      Loading...

    • +

      OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

      12:05 - 12:15  |  Presenting Author(s): Kazuhiko Nakagawa

      • Abstract

      Loading...

    • +

      OA04.06 - Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Initial Findings From the SUMMIT Basket Trial

      12:15 - 12:25  |  Presenting Author(s): Valentina Boni

      • Abstract

      Loading...

    • +

      OA04.07 - Discussant

      12:25 - 12:35  |  Presenting Author(s): Gillianne Geet Yi Lai

      • Abstract

      Abstract not provided

    • +

      OA04.08 - Live Q&A

      12:35 - 12:45

      • Abstract

      Abstract not provided